58
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      Osimertinib for pretreated EGFR Thr790Met-positive advanced non-small-cell lung cancer (AURA2): a multicentre, open-label, single-arm, phase 2 study.

      Read this article at

      ScienceOpenPublisherPubMed
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Osimertinib (AZD9291) is an oral, potent, irreversible EGFR tyrosine-kinase inhibitor selective for EGFR tyrosine-kinase inhibitor sensitising mutations, and the EGFR Thr790Met resistance mutation. We assessed the efficacy and safety of osimertinib in patients with EGFR Thr790Met-positive non-small-cell lung cancer (NSCLC), who had progressed after previous therapy with an approved EGFR tyrosine-kinase inhibitor.

          Related collections

          Author and article information

          Journal
          Lancet Oncol.
          The Lancet. Oncology
          Elsevier BV
          1474-5488
          1470-2045
          Dec 2016
          : 17
          : 12
          Affiliations
          [1 ] The Ottawa Hospital Cancer Centre, University of Ottawa, Ottawa, ON, Canada. Electronic address: ggoss@toh.on.ca.
          [2 ] Department of Chest Medicine, Taipei-Veterans General Hospital and School of Medicine, National Yang-Ming University, Taipei, Taiwan.
          [3 ] Princess Margaret Cancer Centre, Toronto, ON, Canada.
          [4 ] UC San Diego, Moores Cancer Center, La Jolla, CA, USA.
          [5 ] Seoul National University, Bundang Hospital, Seongnam, South Korea.
          [6 ] Division of Chest Medicine, Department of Internal Medicine, Taichung Veterans General Hospital, Taichung, National Yang-Ming University, Taipei, Taiwan.
          [7 ] Perugia University Medical School, Perugia, Italy.
          [8 ] Hyogo Cancer Center, Akashi, Japan.
          [9 ] University of Alberta, Cross Cancer Institute, Edmonton, AB, Canada.
          [10 ] Aichi Cancer Center Hospital, Nagoya, Japan.
          [11 ] National Cancer Center, Goyang-si, Republic of Korea.
          [12 ] La Fe University Hospital, Valencia, Spain.
          [13 ] Duke University Medical Center, Durham, NC, USA.
          [14 ] The Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tokyo, Japan.
          [15 ] The Catholic University of Korea, South Korea.
          [16 ] Hospital de la Santa Creu i Sant Pau, Barcelona, Spain.
          [17 ] AstraZeneca, Cambridge, UK.
          [18 ] AstraZeneca, Alderley Park, UK.
          [19 ] Kindai University Faculty of Medicine, Osaka-Sayama, Japan.
          Article
          S1470-2045(16)30508-3
          10.1016/S1470-2045(16)30508-3
          27751847
          5b69c94d-a165-4893-9132-008bd33f3588
          History

          Comments

          Comment on this article